Wall Street brokerages predict that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will announce earnings of ($0.08) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at ($0.06). Catalyst Pharmaceuticals posted earnings per share of ($0.05) during the same quarter last year, which indicates a negative year-over-year growth rate of 60%. The company is expected to report its next earnings report on Wednesday, August 8th.
According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of ($0.35) per share for the current year, with EPS estimates ranging from ($0.39) to ($0.25). For the next financial year, analysts anticipate that the firm will post earnings of ($0.08) per share, with EPS estimates ranging from ($0.12) to ($0.03). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.06).
A number of brokerages have commented on CPRX. Oppenheimer began coverage on Catalyst Pharmaceuticals in a research note on Thursday, July 12th. They issued a “buy” rating and a $6.00 price target on the stock. ValuEngine raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 14th. Finally, BidaskClub raised Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $6.20.
Shares of Catalyst Pharmaceuticals stock opened at $3.05 on Thursday. Catalyst Pharmaceuticals has a one year low of $2.18 and a one year high of $4.51.
In other Catalyst Pharmaceuticals news, Director Donald A. Denkhaus acquired 20,000 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were purchased at an average cost of $3.75 per share, for a total transaction of $75,000.00. Following the transaction, the director now owns 120,000 shares in the company, valued at $450,000. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders bought 29,000 shares of company stock worth $106,940. Corporate insiders own 9.60% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Two Sigma Securities LLC grew its position in shares of Catalyst Pharmaceuticals by 132.2% in the 4th quarter. Two Sigma Securities LLC now owns 26,658 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 15,178 shares during the last quarter. Tanaka Capital Management Inc. grew its position in shares of Catalyst Pharmaceuticals by 6.4% in the 4th quarter. Tanaka Capital Management Inc. now owns 256,593 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 15,515 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Catalyst Pharmaceuticals by 18.2% in the 1st quarter. California State Teachers Retirement System now owns 133,262 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 20,484 shares during the last quarter. New York State Common Retirement Fund grew its position in shares of Catalyst Pharmaceuticals by 47.6% in the 1st quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 24,200 shares during the last quarter. Finally, Alps Advisors Inc. grew its position in shares of Catalyst Pharmaceuticals by 23.6% in the 1st quarter. Alps Advisors Inc. now owns 137,441 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 26,262 shares during the last quarter. Hedge funds and other institutional investors own 53.28% of the company’s stock.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Featured Story: Understanding Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.